Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
June 21, 2003
Will the addition of paclitaxel to platinum chemotherapy prolong overall survival in patients with platinum-sensitive recurrent ovarian cancer?
Carboplatin or cisplatin every 3 weeks for 6-8 cycles
carboplatin or cisplatin every 3 weeks for 6-8 cycles
Paclitaxel 175 or 185mg/m2 over 3hrs
OS
Recurrent platinum-sensitive (>6-12mo) ovarian cancer
Primary treatment contained platinum chemotherapy
Paclitaxel+platinum vs. platinum-only:
median f/u: 42 mos
median OS: 29 vs. 24 months (SS)
1yr PFS: 50% vs. 40% (SS)
CR or PR: 66% vs. 54% (SS)
more alopecia in paclitaxel-platinum arm
more hematologic toxicity in platinum-only arm
Adding paclitaxel to carboplatin prolongs OS in patients with platinum-sensitive recurrent ovarian cancer.